AbCellera Biologics Inc
ABCLHealthcare|Biotechnology|Canada
$6.79
-0.49 (-6.72%)
DCF (FCF)
$1.87
Tangible Book
$2.81
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07118891 Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | Vasomotor Symptoms Associated With Menopause, Healthy Volunteers | P1P2 | Active | 136 | RCT, Double-blind | ABCL635, Placebo |
| NCT07108894 A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants | Healthy Volunteers | P1 | Active | 40 | RCT, Double-blind | ABCL575, Placebo (Normal Saline 0.9%) |
| NCT04427501 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness | COVID-19 | P2P3 | Completed | 3,307 | RCT, Double-blind | LY3819253, LY3832479, LY3853113, Placebo |
| NCT04497987 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff | COVID-19, SARS-CoV2 | P3 | Completed | 1,180 | RCT, Double-blind | Bamlanivimab, Placebo, Etesevimab |
| NCT04701658 A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) | COVID-19 | P2 | Completed | 109 | Open-label | Bamlanivimab |
| NCT04634409 A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness | COVID-19 | P2 | Completed | 1,755 | RCT, Double-blind | Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab |
| NCT04411628 A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | COVID-19 | P1 | Completed | 26 | RCT, Double-blind | LY3819253, Placebo |
| NCT04603651 Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 | COVID-19 | NO_LONGER_AVAILABLE | — | — | Bamlanivimab |